Investors

We’re dsm-firmenich – innovators in nutrition, health, and beauty

Share price:
Purpose-driven performance
dsm-firmenich brings together two iconic companies. We have deep roots and a bright future, with shared strengths and unrivaled expertise that drive positive impact in everything we do. Our purpose is to bring progress to life – creating a world of potential for customers, communities, consumers, and investors.

Financial calendar

October 31,  2024
Q3 2024 trading update

February 13,  2025
Full-year 2024 results

Contact Investor relations

Whether you’re a shareholder, potential shareholder, or analyst, our Investor relations team is on hand to answer your questions.
Latest news
  • 2 October 2024

    dsm-firmenich completes the sale of yeast extract business to Lesaffre
  • 1 October 2024

    dsm-firmenich completes the sale of its MEG-3® fish oil business to KD Pharma Group SA
  • 8 August 2024

    dsm-firmenich concludes new €1.8 billion Revolving Credit Facility
  • 30 July 2024

    dsm-firmenich reports H1 2024 results
  • 18 July 2024

    dsm-firmenich to sell MEG-3® fish oil business to KD Pharma Group
  • 26 June 2024

    dsm-firmenich issues €800 million long-term bond
  • 14 June 2024

    DSM shareholders can voluntarily transfer their shares to dsm-firmenich before July 2, 2024, 17:45 hours CEST
  • 12 June 2024

    dsm-firmenich announces sale of yeast extract business to Lesaffre
  • 3 June 2024

    dsm-firmenich takes strategic actions to strengthen its position as a leading creation and innovation partner in Nutrition, Health and Beauty
  • 31 May 2024

    dsm-firmenich implements a cross guarantee agreement to mitigate structural subordination and establish a pari-passu debt platform
  • 29 May 2024

    Methane-reducing feed ingredient Bovaer® ready for US market launch
  • 7 May 2024

    dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2024
  • 7 May 2024

    Share repurchase program to cover share plans completed
  • 2 May 2024

    dsm-firmenich Q1 2024 trading update
  • 30 April 2024

    dsm-firmenich's progress on share repurchase program to cover share plans
  • 16 April 2024

    dsm-firmenich completes on-market repurchase of 500,000 shares to cover share plans
  • 8 April 2024

    dsm-firmenich announces repurchase of 1.5m shares to cover share plans
  • 8 March 2024

    dsm-firmenich completes the divestiture of its Jiangshan Vitamin C plant in China
  • 29 February 2024

    dsm-firmenich publishes 2023 Integrated Annual Report
  • 15 February 2024

    dsm-firmenich reports 2023 full year results
  • 14 February 2024

    dsm-firmenich to separate out Animal Nutrition & Health business from the Group
  • 12 February 2024

    dsm-firmenich completes voluntary cash offer for DSM shares
  • 8 January 2024

    dsm-firmenich makes voluntary cash offer for DSM shares
  • 31 October 2023

    dsm-firmenich reports Q3 2023 results
  • 10 October 2023

    dsm-firmenich achieves regulatory clearance in China for two HMO ingredients for early life nutrition
  • 4 October 2023

    dsm-firmenich provides additional pro forma financial information for 2022 and 2023
  • 2 August 2023

    dsm-firmenich reports H1 2023 results
  • 3 July 2023

    dsm-firmenich completes acquisition of postbiotics pioneer Adare Biome
  • 29 June 2023

    dsm-firmenich announces results of extraordinary general meeting of shareholders
  • 28 June 2023

    Trading update and acceleration of strategic actions
  • 22 May 2023

    Emmanuel Butstraen appointed as President of Perfumery & Beauty at dsm-firmenich
  • 22 May 2023

    Bel makes milk low-methane, working across its entire Slovakian dairy chain with partner dsm-firmenich 
  • 17 May 2023

    dsm-firmenich names Katharina Stenholm as Chief Sustainability Officer
  • 9 May 2023

    dsm-firmenich launches as innovators in nutrition, health, and beauty
  • 9 May 2023

    Completion of contribution of Firmenich shares
  • 4 May 2023

    dsm-firmenich announces evolution of CEO structure per 1 September, following completion of the merger
  • 2 May 2023

    DSM provides Q1 2023 trading update
  • 1 May 2023

    Final results of the exchange offer: 96.1% of DSM ordinary shares tendered
  • 18 April 2023

    dsm-firmenich first day of trading on Euronext Amsterdam
Explore more
  • dsm-firmenich at a glance

    Who we are. Why we merged. Where we’re going.

  • Results center

    All the key financial performance information published dsm-firmenich

  • Share center

    All the key details on holding and trading shares of dsm-firmenich.